Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Warrant (NQ:APLMW)

0.0409 +0.0049 (+13.61%)
Streaming Delayed Price Updated: 12:49 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 65,267
Open 0.0363
Bid (Size) 0.0280 (60)
Ask (Size) 0.0300 (4)
Prev. Close 0.0360
Today's Range 0.0271 - 0.0444
52wk Range 0.0052 - 0.0472
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
From Apollomics Inc.
Via GlobeNewswire
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
From Apollomics Inc.
Via GlobeNewswire

Performance

YTD
+339.8%
+339.8%
1 Month
+94.8%
+94.8%
3 Month
+386.9%
+386.9%
6 Month
+339.8%
+339.8%
1 Year
+354.4%
+354.4%

More News

Read More
Keep an eye on the top gainers and losers in Monday's session.
Via Chartmill
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Presentation at the 2024 BIO International Convention
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Private Placement Financing and Addition to Board of Directors
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
From Apollomics Inc.
Via GlobeNewswire
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Apollomics Inc.
Via GlobeNewswire
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
From Apollomics Inc.
Via GlobeNewswire
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
From Apollomics Inc.
Via GlobeNewswire
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
From Apollomics Inc.
Via GlobeNewswire
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
From Apollomics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Apollomics Inc. - Warrant publicly traded?
Yes, Apollomics Inc. - Warrant is publicly traded.
What exchange does Apollomics Inc. - Warrant trade on?
Apollomics Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Apollomics Inc. - Warrant?
The ticker symbol for Apollomics Inc. - Warrant is APLMW on the Nasdaq Stock Market
What is the current price of Apollomics Inc. - Warrant?
The current price of Apollomics Inc. - Warrant is 0.0409
When was Apollomics Inc. - Warrant last traded?
The last trade of Apollomics Inc. - Warrant was at 07/03/25 12:49 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.